Trial AGO-Ovar 2.22

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

AGO-Ovar 2.22

Full title

Eine randomisierte doppelblinde Phase-3-Erhaltungsstudie mit Niraparib versus Placebo bei Patienten mit platinsensitivem Eierstockkrebs

EudraCT number

2013-000685-11

NCT number

NCT01847274

Responsible organization

Frauenklinik GH, Telefon: 089440076800

Classification	Code	Description
ICD-10-GM	C56	Bösartige Neubildung des Ovars
-		Gynecological tumor

Trial type

Interventional

Blinding type

Double blinded

Phase

III

Status

Recruitment finished

Votes

Institutional review board - vote

Unknown

Initiiation & lock

Date of lock (planned / actual)

2021-12-26 / Unknown

	Function	Prename	Surname	Organization
	Principal Investigator	Alexander	Burges	Keine Organisationseinheit angegeben